DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for sudden infant death syndrome — screening already-approved drugs against its 25-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSudden infant death syndrome maps to a 25-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sudden infant death syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) — DYRK1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8T2H · 1.85 Å · ligand (4P)-4-{(3M)-3-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl}pyridin-2-amine (XIR). Experimental structure, not a prediction.
What the evidence adds up to
A 1982 prospective study compared 52 SIDS victims, 36 near-miss infants, and 175 control infants. Nasopharyngitis incidence was roughly 31% across all three groups, but phenothiazine use was significantly higher in SIDS victims (23%) and near-miss infants (22%) than in controls (2%). The authors postulated that phenothiazines, as CNS depressants, may contribute to SIDS occurrence. No subsequent abstract in this set confirms or refutes that finding with further data.
By 1985 and 1986, the cause of SIDS remained unknown despite two decades of intensified research. The 1986 abstract notes that prevalence was unchanged. A 2014 review states that brainstem anomalies are thought to be involved but that the search for mechanisms has been largely unsuccessful. The 2025 abstract calls the aetiopathogenesis undetermined and the cause of death elusive, adding that published hypothetical causes range from the sublime to the ridiculous with no conclusive evidence.
The 2014 review reports that SIDS annually affects one in 3000 babies in the UK and one in 2000 in the USA. The Triple Risk Model describes the confluence of intrinsic infant vulnerability (premature birth, low birth weight, male gender, prenatal smoke exposure), a critical developmental phase at 2–3 months, and exposure to an external stressor. The 2025 abstract identifies prone sleeping position and maternal bed-sharing as outstanding risk factors, and notes that Western public health campaigns promoting supine sleeping have significantly lessened incidence. The 2014 review adds that immigrant groups maintaining traditional sleep ecology in Western environments show substantially lower SIDS rates than the host community.
The 2025 abstract states that research on SIDS incidence, prevalence, and risk factors in Africa has been minimal, and that an international thanatopsy guideline exists but its non-African orientation may overwhelm under-resourced nations. It recommends providing accurate data for research and developing a health awareness programme to reduce risk factors. What is still missing is adequate funding and infrastructure for African research, a standardised thanatopsy protocol suited to local resources, and effective public health campaigns that can contend with cultural rituals and traditions around infant sleep.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 1982 · 67 citations
Phenothiazines and Sudden Infant Death Syndrome
AbstractA relationship between sudden infant death syndrome (SIDS), sleep apnea, and upper airway infections has been reported. The present observation stresses the possible influence of phenothiazine-containing medications and the occurrence of SIDS. The drug is commonly used for the treatment of infants with nasopharyngitis in Belgium and in some other European countries. In a prospective study, 52 SIDS victims, 36 near miss infants, and 175 control infants were compared for the coexistence of nasopharyngitis and phenothiazine treatment in the days preceding death or hospitalization. The incidence of nasopharyngitis was comparable in the three groups (approximately 31%), but phenothiazines were used significantly more frequently in SIDS victims (23%) and near miss infants (22%) than in control subjects (2%). It is postulated that phenothiazines, as CNS depressors, may contribute to the occurrence of SIDS.
New England Journal of Medicine · 1986 · 25 citations
Sudden Infant Death Syndrome
AbstractSudden infant death syndrome (SIDS) is the most common diagnosis in infants who die at one month to one year of age. After two decades of increased public awareness and intensified research into the causes and prevention of SIDS, its cause or causes are unknown and its prevalence is unchanged. In this issue of the Journal, Bass and associates report on 26 consecutive cases of sudden unexpected death in young infants, in 23 of whom the medical examiner subsequently diagnosed SIDS.1 Bass et al. conducted an independent detailed investigation of the scene of death. On the basis of this . . .
Journal of the Islamic Medical Association of North America · 1985 · 3 citations · open access
Sudden Infant Death Syndrome: An Update
AbstractThe sudden infant death syndrome (SIDS) accounts for most of the deaths in infancy. The precise etiology of this condition, despite extensive research, remains unknown. Each year additional studies advance newer explanations. In this paper an attempt is made to review the old and the new theories explaining why an apparently healthy infant dies. The pathological investigations in the past have not contributed substantially in solving the mystery of the SIDS etiology. The clinical studies also have not provided complete answers but they have helped recognize the entity of near-SIDS paving the way to possible prevention of the SIDS. Current thinking on this subject is presented for the primary care physicians and the researchers.
Evolution Medicine and Public Health · 2014 · 1 citations · open access
SIDS and Infant Sleep Ecology
AbstractSudden infant death syndrome (SIDS) is the designation given to the unexpected death of an infant that remains unexplained following post-mortem, death scene investigation and review of clinical history [1]. The search for mechanisms underlying such deaths has been largely unsuccessful; brainstem anomalies are thought to be involved. Although rare SIDS is the leading category of non-accidental deaths between 1 month and 1 year of age, annually affecting one in 3000 babies in the UK and one in 2000 in USA. Key associations with SIDS are identified using retrospective studies of SIDS-cases and matched controls. Three key factors identified are: ‘Intrinsic infant vulnerability’ (premature birth, low birth weight, male gender and prenatal smoke exposure). Death during sleep (night or day) is typical, with peak prevalence during a ‘critical developmental phase’ at 2–3 months of age. Thirdly SIDS deaths involve ‘exposure to an external stressor’, a feature of sleep ecology imposing a physiological challenge on the infant. The confluence of an external stressor, a critical developmental period, and an intrinsically vulnerable infant are encapsulated in the Triple Risk Model for SIDS [2]. SIDS-deaths are a phenomenon of infant sleep in Western post-industrialized cultures, normally occurring while infants are alone. This pattern implicates aspects of infant sleep ecology prevalent in contemporary Euro-American societies that are incongruent with evolved infant physiology [3]. Immigrant groups who maintain their ‘traditional’ sleep ecology in ‘Western’ environments typically exhibit substantially lower SIDS rates than the host community [4]. Comparative evolutionary studies indicate that human infants are poorly neurologically developed at birth, requiring close physical contact for safety, physiological regulation and frequent feeding. Our species-specific sleep ecology involves close contact with a carer and frequent sleep arousals for the first 6 months of life [3]. Contemporary Euro-American sleep ecology encourages and values solitary and prolonged infant sleep from an early age, in combination with artificial milk feeding and the use of ‘sleep aids’ (such as pacifiers, white noise, swinging cradles and swaddling) to encourage infants to sleep deeply with minimal arousals. Inhibition of the arousal response is a characteristic of vulnerable babies and is enhanced by external stressor exposure [5]. Infant care strategies that promote early sleep independence fail to provide infants with arousal support during the critical physiological transitions that characterize the early months of life. Current SIDS prevention relies on identifying discrete sleep-related risks (such as prone position, soft surfaces) and advising parents to avoid these ‘modifiable risk-factors’ [2]. An evolutionary perspective suggests a more holistic view of infant sleep ecology is warranted. Clinicians can discourage infant-care trends that fail to support normal infant physiology (such as prolonged solitary sleep and early sleep consolidation), encourage parental proximity and responsive care, and educate parents about infant developmental needs.
Medical Journal of Zambia · 2025 · 1 citations · open access
Sudden Infant Death Syndrome: an infantile death-bed misadventure
AbstractA case of Sudden Infant Death Syndrome, aka cot-death is reported. The significance of Sudden Infant Death Syndrome in Zambia is highlighted. The objective is to shine the spotlight on a preventable cause of death in Africa, and the research work and public health campaigns to reduce infant mortality. Sudden Infant Death Syndrome has been defined as an unexpected death of an infant under twelve months old whilst asleep and which remains unexplained after reviewing the clinical history, performing an adequate thanatopsy investigation and examining the scene of death. The aetiopathogenesis is yet to be determined and the cause of death remains elusive. The clinical features are non-specific, and typically an asymptomatic healthy baby is found dead whilst asleep. The diagnosis is reached by excluding any other cause of death. This may pose a diagnostic challenge when there is a concomitant disease which might be a coincidental finding but not the cause of death. In the case reported, a thanatopsy examination followed up by ancillary investigations assisted in determining the cause of death. A suspicion of suffocation by maternal overlaying may not be substantiated without distinguishing signs of trauma. A concealed infanticide may be overlooked and misdiagnosed as a cot-death. There is no legal definition of a cause of death, and it is at best an informed clinical opinion, not a medical fact. It is important to be accurate and interpret the subtle findings carefully. It may be ethically wise to err on the side of caution and not risk a miscarriage of justice. Since Sudden Infant Death Syndrome is due to a natural cause for registration purpose, there were no judicial proceedings. The bereaved family were consoled and the essentials of the cause of death were sensitively explained to bring about a satisfactory outcome. There has been an assortment of hypothetical causes of Sudden Infant Death Syndrome ranging from the sublime to the ridiculous, published in the medical literature but lacking any conclusive evidence. The outstanding risk factors have been identified as prone sleeping position and sharing maternal bed. The public health campaigns in the Western world have reinforced the supine safe-sleeping position for infants and significantly lessened the incidence of infant deaths. The research studies on the incidence and prevalence, and risk factors of Sudden Infant Death Syndrome in Africa have been minimal. They are a prerequisite for the development and implementation of a standardized thanatopsy protocol for investigating deaths in infancy. An international thanatopsy guideline has been developed but its non-African orientation may overwhelm under-resourced African nations. A public health campaign in Africa has to compete with the challenges of cultural rituals and traditions of infant sleeping position and maternal bed-sharing, perpetuated by community elders. Recommendations are made for the provision of accurate data for research work and development of a health awareness programme to reduce the risk factors of Sudden Infant
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
